US20050239874A1 - Novel analgesic and immunomodulatory cannabinoids - Google Patents
Novel analgesic and immunomodulatory cannabinoids Download PDFInfo
- Publication number
- US20050239874A1 US20050239874A1 US11/127,455 US12745505A US2005239874A1 US 20050239874 A1 US20050239874 A1 US 20050239874A1 US 12745505 A US12745505 A US 12745505A US 2005239874 A1 US2005239874 A1 US 2005239874A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- och
- alkyl group
- halogen
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [2*]C1CC[C@H]2COC3=C(C(O)=CC(C)=C3)[C@@H]2C1 Chemical compound [2*]C1CC[C@H]2COC3=C(C(O)=CC(C)=C3)[C@@H]2C1 0.000 description 27
- RKVHHNKIDOWVPY-UHFFFAOYSA-N CC.CC12CC3CC(CC(C3)C1)C2 Chemical compound CC.CC12CC3CC(CC(C3)C1)C2 RKVHHNKIDOWVPY-UHFFFAOYSA-N 0.000 description 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N CC1CCCC1 Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 2
- RNHAZKBOGKEYRF-XOUSQUCASA-N C.C.CC1CC[C@@H]2[C@@H](C1)C1=C(C=CC=C1O)OC2(C)C.CC1CC[C@H]2C(=O)OC3=C(C(O)=CC=C3)[C@@H]2C1 Chemical compound C.C.CC1CC[C@@H]2[C@@H](C1)C1=C(C=CC=C1O)OC2(C)C.CC1CC[C@H]2C(=O)OC3=C(C(O)=CC=C3)[C@@H]2C1 RNHAZKBOGKEYRF-XOUSQUCASA-N 0.000 description 1
- ONFZIZIBWPJURI-UHFFFAOYSA-N C1CC2CCC(C1)C2.C1CC2CCC1CC2.C1CC2CCCC(C1)C2.C1CC2CCCC(C1)CC2 Chemical compound C1CC2CCC(C1)C2.C1CC2CCC1CC2.C1CC2CCCC(C1)C2.C1CC2CCCC(C1)CC2 ONFZIZIBWPJURI-UHFFFAOYSA-N 0.000 description 1
- VBYHFOJFSLKBDH-UHFFFAOYSA-N CC(CC1)(CCC1(N)N)N Chemical compound CC(CC1)(CCC1(N)N)N VBYHFOJFSLKBDH-UHFFFAOYSA-N 0.000 description 1
- HHELHPPFEWCBOW-DGLONNOTSA-N CC1=CC[C@@H]2[C@@H](C1)C1=C(C=C(C3CC4CCC3(C)C4(C)C)C=C1O)OC2(C)C.CC1=CC[C@@H]2[C@@H](C1)C1=C(C=C(C3CC4CCC3(C)C4(C)C)C=C1O)OC2(C)C.CCCCCC1=CC2=C(C(O)=C1)[C@@H]1CC(C)=CC[C@H]1C(C)(C)O2.CCCCCCC1(C2=CC3=C(C(O)=C2)[C@@H]2CC(C)=CC[C@H]2C(C)(C)O3)OCCO1.CCCCCCC1(C2=CC3=C(C(O)=C2)[C@@H]2CC(C)=CC[C@H]2C(C)(C)O3)SCCS1 Chemical compound CC1=CC[C@@H]2[C@@H](C1)C1=C(C=C(C3CC4CCC3(C)C4(C)C)C=C1O)OC2(C)C.CC1=CC[C@@H]2[C@@H](C1)C1=C(C=C(C3CC4CCC3(C)C4(C)C)C=C1O)OC2(C)C.CCCCCC1=CC2=C(C(O)=C1)[C@@H]1CC(C)=CC[C@H]1C(C)(C)O2.CCCCCCC1(C2=CC3=C(C(O)=C2)[C@@H]2CC(C)=CC[C@H]2C(C)(C)O3)OCCO1.CCCCCCC1(C2=CC3=C(C(O)=C2)[C@@H]2CC(C)=CC[C@H]2C(C)(C)O3)SCCS1 HHELHPPFEWCBOW-DGLONNOTSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- ⁇ 8 -Tetrahydrocannabinol the pyschoactive marijuana derived cannabinoid, binds to the CB1 receptor in the brain and to the CB2 receptor in the spleen.
- Compounds which stimulate the CB1 receptor have been shown to induce analgesia and sedation, to cause mood elevation, to control nausea and appetite and to lower intraocular pressure (Mechoulam, Cannabinoids as Therapeutic Agents, CRC Press, Boca Raton, Fla. (1986), Fride and Mechoulam, Eur. J. Pharmacol. 231:313 (1993), Crawley et al., Pharmacol. Biochem. Behav. 46:967 (1993) and Smith et al., J. Pharm.
- cannabinoids with a monocyclic, a fused bicyclic, a bridged bicyclic or a bridged tricyclic side chain at the C-3 position show improved binding affinities for the CB1 and/or CB2 receptor compared with known cannabinoids, which typically have a linear side chain at the C-3 position.
- the cannabinoids AMG3 and AMG14 have a K i for the CB1 receptor of less than 1.0 nM and AM731 and-AM732 have a K i for the CB2 receptor of less than 10.0 nM (Example 2).
- the K i of ⁇ 8 -tetrahydrocannabinol for the CB1 and CB2 receptors is only 45 nM and 14 nM, respectively.
- the structures of these compounds are shown below. Based on these results, novel cannabinoids with increased binding affinity for the CB1 and CB2 receptors are disclosed. Also disclosed are methods of stimulating a CB1 and/or CB2 receptor in a subject.
- One embodiment of the present invention is a compound represented by Structural Formula (I): R—X—Y; (I) and physiologically acceptable salts thereof.
- R is a tricyclic core of a cannabinoid or substituted cannabinoid.
- X is covalent bond, —CH— or —CHR 1 —, wherein R 1 is a C1 to C3 substituted or unsubstituted alkyl group.
- Y is a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system.
- Another embodiment of the present invention is a method of stimulating a CB1 and/or CB2 receptor in a subject.
- the method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I).
- novel compounds of the present invention can be used to stimulate the CB1 or CB2 receptors in a subject at lower doses and higher selectivity than other known CB1 or CB2 receptor agonists.
- they are expected to produce fewer side-effects than known CB1 or CB2 receptor agonists when used for treatment, for example, in treating glaucoma, treating autoimmune disease (e.g., lupus erythematosus, rheumatoid arthritis, psoriasis, multiple sclerosis and inflammatory bowel disease such as ulcerative colitis and Crohn's disease), preventing tissue rejection in organ transplant patients, controlling nausea in patients undergoing chemotherapy and enhancing appetite and controlling pain in individuals with AIDS Wasting Syndrome.
- some of these compounds are selective agonists for either the CB1 (e.g., AM411) or CB2 receptor (e.g., AM731 and AM732).
- FIGS. 1A, 1B and 1 C show the structure of a number of examples of novel compounds included in the present invention.
- FIGS. 2A and 2B show the structure of a number of novel cannabinoid side chains which can be found in the compounds of the present invention.
- FIG. 3 is a schematic showing a general procedure for the preparation of ⁇ 8 -tetrahydrocannabinol analogs and 2- and 4-substituted deoxy- ⁇ 8 -tetrahydrocannabinols.
- FIG. 4 is a schematic of the synthesis of cannabinol analogs with noncyclic side chains.
- FIGS. 5A and 5B are schematics showing the preparation of the rescorinol starting materials used in the syntheses shown in FIGS. 3 and 4 .
- Cannabinoids have a core tricyclic ring system in which a monohydroxylated phenyl ring and a six membered ring are each fused to a central pyran ring or to a central six-membered lactone ring (preferably to a pyran ring).
- cannabinoids are able to induce characteristic physiological effects in mammals, including euphoria, delerium, drowsiness, halluncinations, weakness and/or hyporeflexia.
- the tricyclic core ring system of many cannabinoids is shown in Structural Formula (II).
- cannabinoids have the tricyclic core shown in Structural Formula (II), modified to include one or more double bonds in Ring A, for example, a double bond between carbons 8 and 9, between carbons 9 and 10 or between carbons 9 and 11.
- cannabinoids have the core structures described above, modified so that the methyl group bonded to carbon 11 has been replaced, for example, with a hydrogen, hydroxyl, hydroxymethyl, halogen (e.g., chloro, bromo, iodo and fluoro), methoxy, ethoxy, nitrile, nitro, halogenated methyl, halogenated ethyl, methoxymethyl, ethoxymethyl, nitromethyl, ethyl or —CH 2 CN group.
- halogen e.g., chloro, bromo, iodo and fluoro
- the hydroxyl group at position 1 of the core structure is replaced with —H, —OCH 3 , —NH 2 or —NHCH 3 .
- the term —cannabinoid— also refers to other compounds which: 1) induce one or more of the physiological effects described above which are characteristic of the cannabinoids and 2) have core structures which are related to Structural Formula (II). Also shown in Structural Formula (II) is a numbering system for the atoms in the core tricylic structure.
- Cannabinoids also generally have a linear alkyl side chain at position C-3 of the cannabinoid core.
- the linear alkyl side chain is replaced with a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system.
- Suitable substituents for a cannabinoid include groups which do not significantly diminish the ability of a cannabinoid to activate a cannabinoid receptor. Substitutions can occur at positions 2, 4, 6a-10a or at the three methyl groups. Substitutions at more than one position are possible. Substituents which do no significantly diminish the biological activity of cannabinoids are generally small, pharmacophoric groups.
- Examples include —H, —OH, —OCH 3 , —OCH 2 CH 3 , halogen (e.g., chloro, bromo, iodo and fluoro), —CN, azido, isocyanate, isothiocyanate, —NO 2 , —CH 3 , —C(halogen) 3 , —CH 2 O H, 13 CH 2 OCH 3 , —CH 2 OCH 2 CH 3 , —CH 2 (halogen), —CH 2 CN, —CH 2 NO 2 , —CH 2 CH 3 , —CH 2 C(halogen) 3 , —CH 2 NH 2 , —CH 2 NHCH 3 or —CH 2 N(CH 3 ) 2 .
- halogen e.g., chloro, bromo, iodo and fluoro
- —CN azido, isocyanate, isothiocyanate, —NO 2 , —CH 3 ,
- Suitable substituents can be identified by testing modified cannabinoids in the in vitro CB1 or CB2 assays described in Example 2.
- Cannabinoids with other substituents can be prepared by modification of the synthetic procedures described in Example 1, e.g., by replacing alcohol (A) in the synthesis shown in FIG. 3 or by replacing the ester/ketone starting material in FIG. 4 with suitably substituted analogs.
- the tricyclic cannabinoid core is represented by Structural Formula (III):
- Ring A has from zero to three endocyclic double bonds. Examples include wherein Ring A is completely saturated, wherein Ring A has three double bonds and wherein Ring A as one endocyclic double bond which connects carbons 9 and 10 or 9 and 11. Preferably, Ring A has one endocyclic double bond wich connects carbons 8 and 9. As used herein, a double bond between two ring atoms is an “endocyclic” double bond.
- Z is >C(CH 3 ) 2 or —C ⁇ O. Z is preferably >C(CH 3 ) 2 .
- R 2 is —H, —OH, —OCH 3 , —OCH 2 CH 3 , halogen (e.g., chloro, bromo, iodo and fluoro), —CN, —NO 2 , —CH 3 , —C(halogen) 3 , —CH 2 OH, —CH 2 OCH 3 , —CH 2 OCH 2 CH 3 , —CH 2 (halogen), —CH 2 CN, —CH 2 NO 2 , —CH 2 CH 3 , —CH 2 C(halogen) 3 , —CH 2 NH 2 , —CH 2 NHCH 3 or —CH 2 N(CH 3 ) 2 .
- R 2 is —CH 3 or —CH 2 OH.
- X and Y taken together, are a C5-C7 carbocyclic ring, a substituted C5-C7 carbocyclic ring, a C5-C7 heterocyclic ring or a C5-C7 substituted heterocyclic ring.
- Carbocyclic rings are non-aromatic rings which have only carbon as the ring atoms.
- carbocyclic rings include from about five to about seven ring carbons and are substituted or unsubstituted. Examples include substituted and unsubstituted cyclopentane, cyclopentene, cyclohexane, cyclohexene, cycloheptane and cycloheptene.
- a preferred example is a substituted cyclohexane shown below in Structural Formula (IV):
- R 3 is —H or —CH 3 .
- R 4 and R 5 are independently —H, a C1-C8 straight chained alkyl group or a C1-C8 substituted straight chained alkyl group.
- at least one of R 4 and R 5 is —H.
- Heterocyclic rings are non-aromatic rings with carbon and one or more heteroatoms such oxygen, nitrogen and/or sulfur as ring atoms.
- heterocyclic rings contain from about five to about seven ring atoms and are substituted or unsubstituted.
- Preferred examples of heterocyclic rings are shown below in Structural Formulas (V) and (VI):
- Z′ and Z′′ are independently —S—, —O—, —S(O)— or —N(R 7 )—.
- Z′ and Z′′ are each —O— 0 or —S—.
- R 6 is a C1 to about C12 straight chained alkyl or substituted alkyl group. Preferably, R 6 is a C4 to C10 alkyl group.
- R 7 is —H or —CH 3 .
- hetetocyclic rings include substituted and unsubstituted 1,3-dioxane, 1,4-dioxane, 1,3-dithiane, 1,4-dithiane, diazetane, tetrahydrofuran, tetrahyrothiophene, morpholine, thiomorpholine, pyrrolidine, piperazine, piperidine and thiazolidine.
- a fused bicyclic ring comprises two rings which share two ring atoms. Examples include systems such as decalin and tetralin.
- a preferred example of a fused bicyclic ring system is represented by Structural Formula (VII):
- R 8 is —H or —CH 3 ;
- R 9 is —H, a C1-C4 alkyl group or a C1-C4 substituted or unsubstituted alkyl group.
- a “bridged bicyclic ring” has two rings in which more than two ring atoms are shared by the two rings.
- a bicyclic ring can have one or more ring heteroatoms such as oxygen, sulfur or nitrogen.
- a preferred bridged bicyclic ring is a substituted or unsubstituted 2.2.1 seven-membered system also referred to as a “norbornyl group”. Examples of norbornyl groups are represented by Structural Formula (VIII) and (IX);
- R 10 -R 12 are independently —H, C1-C3 alkyl group or C1-C3 substituted alkyl group.
- R 10 -R 12 are independently —H or —CH 3 .
- bridged bicyclic structures include a 3.2.1 eight-membered bicyclic structure, a 3.3.1 nine-membered bicyclic structure and a 2.2.2 eight-membered structure and a 3.3.2 nine-membered structure.
- the structures of a 3.2.1 eight-membered bicyclic system, a 3.3.1 nine-membered bicyclic system, a 2.2.2 eight-membered. bicyclic system and a 3.3.2 nine-membered bicyclic system are provided by Structural Formulas (X)-(XIII):
- the bridged bicyclic structures represented by Structural Formulas (X)-(XIII) are substituted by one or more methyl groups.
- bridged bicyclic and tricyclic ring systems indicates the number of ring atoms between bridgeheads.
- a “bridgehead” is an atom shared by both rings.
- bicyclo 2.2.1. heptane shown in Structural Formula (VIII) has two (C-2 and C-3), two (C-5 and C-6) and one (C-7) carbons between the bridgeheads (C-1 and C-4).
- the numbering scheme for the ring atoms in 2.2.1 heptane is also shown in Structural Formula (VIII).
- Bridged tricyclic ring systems comprise three rings, each of which shares two or more ring atoms with each of the other two rings.
- a bridged tricyclic ring can have one or more heteroatoms such as oxygen, nitrogen or sulfur.
- a preferred example is a substituted or unsubstituted 1,1,1,1,1,1-tricyclic ten-membered ring system, also referred to as an “adamantyl” group. Examples of adamantyl groups are represented by Structural Formula (XIV)-(XVII):
- R 13 , R 14 , R 15 and R 16 are independently —H, a C1-C3 alkyl group or a C1 to C3 substituted alkyl group.
- R 13 is —CH 3 .
- X 1 and X 2 independently are >N— or >CH—.
- X 1 and X 2 are >CH—.
- novel cannabinoid analogs of the present invention are represented by Formula (III), modified so that the hydroxyl group attached to the phenyl ring is replaced with an —H and/or modified so that the side chain is attached to position four of the tricyclic cannabinoid core.
- bridged tricyclic system is a substituted or unsubstituted 0,1,1,1,1,1-tricyclic nine-membered ring system.
- Suitable substituents for a carbocyclic ring, a heterocyclic ring, a fused bicyclic ring, a bridged bicyclic ring and a bridged tricyclic ring are generally C1-C8 alkyl groups, substituted C1-C8 alkyl groups and small, pharmacophoric groups.
- small, pharmacophoric groups include, but are not limited to, —H, —OH, —OCH 3 , —OCH 2 CH 3 , halogen (e.g., chloro, bromo, iodo and fluoro), —CN, azido, isocyanate, isothiocyanate, —NO 2 , —CH 3 , —C(halogen) 3 , —CH 2 OH, —CH 2 OCH 3 , —CH 2 OCH 2 CH 3 , —CH 2 (halogen) , —CH 2 CN, —CH 2 NO 2 , —CH 2 CH 3 , —CH 2 C(halogen) 3 , —CH 2 NH 2 , —CH 2 NHCH 3 or —CH 2 N(CH 3 ) 2 .
- Alkyl groups can be straight chained or branched. Suitable substituents for an alkyl group include small, pharmacophoric groups, as described above.
- FIGS. 1 and 2 Specific examples of the compounds of the present invention are shown in FIGS. 1 and 2 .
- the single or double bond by which a chemical group or moiety is connected to the remainder of the molecule or compound is indicated by the following symbol:
- the corresponding symbol in Structural Formula (VIII) indicates that the norbornyl group, which is represented in Structural Formula (I) by Y, is connected to R or X in Structural Formula (I) by a single covalent bond with between carbon three of the norbornyl group and R or X.
- a “therapeutically effective amount” is the quantity of compound which results in a desired therapeutic effect in a subject, e.g., immune system-suppression, decreased nausea in patients undergoing chemotherapy, increased appetite and/or decreased pain in individuals with AIDS Wasting Syndrome or intraocular pressure in individuals with glaucoma.
- the specific dosage level of active ingredient will depend upon a number of factors, including, for example, biological activity of the particular preparation, age, body weight, sex and general health of the subject being treated.
- a “therapeutically effective amount” of the compound ranges from about 10 mg/day to about 1000 mg/day, preferably from about 50 mg/day to about 500 mg/day.
- a “subject” refers to a human.
- An “animal” refers to veterinary animals, such as dogs, cats, horses, and the like, and farm animals, such as cows, pigs, guinea pigs and the like.
- the compounds of the present invention can be administered by a variety of known methods, including orally, rectally, or by parenteral routes (e.g., intramuscular, intravenous, subcutaneous, nasal or topical).
- parenteral routes e.g., intramuscular, intravenous, subcutaneous, nasal or topical.
- the form in which the compounds are administered will be determined by the route of administration.
- Such forms include, but are not limited to capsular and tablet formulations (for oral and rectal administration), liquid formulations (for oral, intravenous, intramuscular or subcutaneous administration) and slow releasing microcarriers (for rectal, intramuscular or intravenous administration).
- the formulations can also contain a physiologically acceptable vehicle and optional adjuvants, flavorings, colorants and preservatives.
- Suitable physiologically acceptable vehicles may include saline, sterile water, Ringer's solution, and isotonic sodium chloride solutions.
- the compounds of the present invention can be prepared by the syntheses shown in FIGS. 3-5 . Specific conditions for reactions shown in FIGS. 3-5 are provided in Example 1.
- Salts of compounds containing a phenolic group or other acidic functional group can be prepared by reacting with a suitable base, for example, a hydroxide base or amine base.
- Salts of acidic functional groups contain a countercation such as sodium, potassium, ammonium and the like.
- Salts of compounds containing an amine or other basic group can be obtained, for example, by reacting with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like.
- Compounds with quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like.
- the disclosed cannabinoids can be used to screen for cells which express cannabinoid receptors (CB1 or CB2).
- CB1 or CB2 cannabinoid receptors
- the cells are contacted with a radiolabelled cannabinoid, washed to remove unbound compound and then counted to assess retained radioactivity.
- Cells which retain radioactivity bind cannabinoids and are there likely to express a cannabinoid receptor.
- the cannabinoid is a CB1 or CB2 selective cannabinoid and therefore identifies cells which express the CB1 or CB2 receptor, respetively.
- the disclosed cannabinoids can also be used to identify other compounds which bind to a cannabinoid receptor.
- radiolabelled cannabinoids can be used in place of CP-55,940 in the CB1 or CB2 assay described in Example 1.
- Radiolabeled cannabinoids can be prepared by, for example, by reducing the ketones used in Method II of FIG. 5 with a suitable radiolabeled reducing agent such a tritiated sodium borohydride and oxidizing back to the ketone with a suitable oxidizing agent such as pyridinium chloro chromate (PCC).
- PCC pyridinium chloro chromate
- the cannabinoid is selective for the CB1 or CB2 receptor.
- a mixture of 100 mmol resorcinol and 100 mmol tertiary alcohol in 200 ml of 70% methanesulfonic acid was stirred at 0° C. for 12 hours for the preparation of linear side chain resorcinols, and stirred for 3 to 4 hours at room temperature for preparation of cyclic side chain resorcinols.
- the reaction was quenched by addition of an excess of water.
- the crude product was purified by column chromatography. The column was eluted with 2:1 mixture of. petroleum ether and acetone. Yield was about 70%.
- rat forebrain membranes were prepared as described by the method of Dodd et al., Brain Res. 226:107 (1981), the entire teachings of which are incorporated herein by reference. Rat whole brains minus the cerebral cortex were diced with a razor blade and homogenized in 0.32 M sucrose, pH 7.4. The resulting suspension was spun at 400 ⁇ g at 4° C. The supernatant was decanted and layered over 1.2 M sucrose in TME buffer (25 mM Tris base, 5 mM MgCl 2 1 mMEDTA, pH 7.4) and spun at 109,000 ⁇ g.
- TME buffer 25 mM Tris base, 5 mM MgCl 2 1 mMEDTA, pH 7.4
- the interface containing plasma membrane protein was collected, pooled and layered over 0.8 M sucrose in TME, pH 7.4. The pellet was carefully resuspended in TME, pH 7.4 and the total protein content was assayed by the method of Markwell et al., Anal. Biochem. 87:206 (1978), the entire teachings of which are incorporated herein by reference. Protein was aliquotted, frozen under liquid nitrogen and stored at ⁇ 80° C. until use.
- Nonspecific binding was assessed using 100 nM CP-55,940. Data collected from three independent experiments performed with duplicate determinations were normalized between 100% and 0% specific binding for [H 3 ]CP-55,940, determined using buffer and 100 nM CP-55,940. The normalized data was analyzed using a 4 parameter nonlinear logistic equation to yield IC 50 values. Data from at least two independent experiments performed in duplicate were used to calculate IC 50 values which were convered to K i values using the assumptions of Cheng and Prusoff, Biochem. Pharmacol., 22:3099 (1973), the entire teachings of which are incorporated herein by reference.
- Mouse spleen was used a source of CB2 receptors to assess binding affinity of analogs described in this invention.
- the CB2 binding assay was conducted in the same manner as for CB1. Silanized centrifuge tubes were used throughout to minimize receptor loss due to adsorption.
- K i s (nanomolar) for a number of the compounds of the present invention are shown in the Table below: TABLE K i in nM for the K i in nM for the Compound CB1 Receptor CB2 Receptor AM405 19.1 AM406 14.5 AM410 25.8 22.3 AM409 75.3 AM407 9.1 AM408 18.3 AM412 182.9 85.0 AMG3 0.32 1.7 AMG9 3.6 AMG14 0.2 AM411 6.9 52.0 AM722 78.2 40.3 AM729 29.3 26.9 AM723 382.6 2845.0 AM728 30.7 32.8 AM731 60.6 6.1 AM732 20.1 2.0
Abstract
Disclosed are novel compounds represented by the following structural formula:
R—X—Y; and physiologically acceptable salts thereof. R is a tricyclic core of a cannabinoid or substituted cannabinoid.
R—X—Y; and physiologically acceptable salts thereof. R is a tricyclic core of a cannabinoid or substituted cannabinoid.
X is a covalent bond, —CH2— or —CHR1—, wherein R1 a C1 to C3 substituted or unsubstituted alkyl group. Y is a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system. Also disclosed is a method of stimulating a CB1 and/or CB2 receptor in a subject. The method comprises administering to the subject a therapeutically effective amount of R—X—Y.
Description
- This application claims the benefit of U.S. Provisional Application No. 60/084,008, filed May 4, 1998, the contents of which are incorporated herein by reference in their entirety.
- The invention was supported, in whole or in part, by grants DA3801 and DA9158 from the National Institute of Drug Abuse (NIDA). The Government has certain rights in the invention.
- Δ8-Tetrahydrocannabinol, the pyschoactive marijuana derived cannabinoid, binds to the CB1 receptor in the brain and to the CB2 receptor in the spleen. Compounds which stimulate the CB1 receptor have been shown to induce analgesia and sedation, to cause mood elevation, to control nausea and appetite and to lower intraocular pressure (Mechoulam, Cannabinoids as Therapeutic Agents, CRC Press, Boca Raton, Fla. (1986), Fride and Mechoulam, Eur. J. Pharmacol. 231:313 (1993), Crawley et al., Pharmacol. Biochem. Behav. 46:967 (1993) and Smith et al., J. Pharm. Exp. Therap. 270:219 (1994)). Compounds which stimulate the CB2 receptor have been shown to suppress the immune system (Mechoulam, Cannabinoids as Therapeutic Agents, CRC Press, Boca Raton, Fla. (1986), Fride and Mechoulam, Eur. J. Pharmacol. 231:313 (1993), Crawley et al., Pharmacol. Behav. 46:967 (1993) and Smith et al., J. Pharm. Exp. Therap. 270:219 (1994)).
- Disclosed herein is the discovery that cannabinoids with a monocyclic, a fused bicyclic, a bridged bicyclic or a bridged tricyclic side chain at the C-3 position show improved binding affinities for the CB1 and/or CB2 receptor compared with known cannabinoids, which typically have a linear side chain at the C-3 position. For example, the cannabinoids AMG3 and AMG14 have a Ki for the CB1 receptor of less than 1.0 nM and AM731 and-AM732 have a Ki for the CB2 receptor of less than 10.0 nM (Example 2). In contrast, the Ki of Δ8-tetrahydrocannabinol for the CB1 and CB2 receptors is only 45 nM and 14 nM, respectively. The structures of these compounds are shown below.
Based on these results, novel cannabinoids with increased binding affinity for the CB1 and CB2 receptors are disclosed. Also disclosed are methods of stimulating a CB1 and/or CB2 receptor in a subject. - One embodiment of the present invention is a compound represented by Structural Formula (I):
R—X—Y; (I)
and physiologically acceptable salts thereof. - R is a tricyclic core of a cannabinoid or substituted cannabinoid.
- X is covalent bond, —CH— or —CHR1—, wherein R1 is a C1 to C3 substituted or unsubstituted alkyl group.
- Y is a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system.
- Another embodiment of the present invention is a method of stimulating a CB1 and/or CB2 receptor in a subject. The method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I).
- The novel compounds of the present invention can be used to stimulate the CB1 or CB2 receptors in a subject at lower doses and higher selectivity than other known CB1 or CB2 receptor agonists. Thus, they are expected to produce fewer side-effects than known CB1 or CB2 receptor agonists when used for treatment, for example, in treating glaucoma, treating autoimmune disease (e.g., lupus erythematosus, rheumatoid arthritis, psoriasis, multiple sclerosis and inflammatory bowel disease such as ulcerative colitis and Crohn's disease), preventing tissue rejection in organ transplant patients, controlling nausea in patients undergoing chemotherapy and enhancing appetite and controlling pain in individuals with AIDS Wasting Syndrome. In addition, some of these compounds are selective agonists for either the CB1 (e.g., AM411) or CB2 receptor (e.g., AM731 and AM732).
-
FIGS. 1A, 1B and 1C show the structure of a number of examples of novel compounds included in the present invention. -
FIGS. 2A and 2B show the structure of a number of novel cannabinoid side chains which can be found in the compounds of the present invention. -
FIG. 3 is a schematic showing a general procedure for the preparation of Δ8-tetrahydrocannabinol analogs and 2- and 4-substituted deoxy-Δ8-tetrahydrocannabinols. -
FIG. 4 is a schematic of the synthesis of cannabinol analogs with noncyclic side chains. -
FIGS. 5A and 5B are schematics showing the preparation of the rescorinol starting materials used in the syntheses shown inFIGS. 3 and 4 . - Cannabinoids have a core tricyclic ring system in which a monohydroxylated phenyl ring and a six membered ring are each fused to a central pyran ring or to a central six-membered lactone ring (preferably to a pyran ring). In addition, cannabinoids are able to induce characteristic physiological effects in mammals, including euphoria, delerium, drowsiness, halluncinations, weakness and/or hyporeflexia. The tricyclic core ring system of many cannabinoids is shown in Structural Formula (II). Other cannabinoids have the tricyclic core shown in Structural Formula (II), modified to include one or more double bonds in Ring A, for example, a double bond between carbons 8 and 9, between carbons 9 and 10 or between carbons 9 and 11. Yet other cannabinoids have the core structures described above, modified so that the methyl group bonded to carbon 11 has been replaced, for example, with a hydrogen, hydroxyl, hydroxymethyl, halogen (e.g., chloro, bromo, iodo and fluoro), methoxy, ethoxy, nitrile, nitro, halogenated methyl, halogenated ethyl, methoxymethyl, ethoxymethyl, nitromethyl, ethyl or —CH2CN group. In other cannabinoids, the hydroxyl group at
position 1 of the core structure is replaced with —H, —OCH3, —NH2 or —NHCH3. The term —cannabinoid—, as it is used herein, also refers to other compounds which: 1) induce one or more of the physiological effects described above which are characteristic of the cannabinoids and 2) have core structures which are related to Structural Formula (II). Also shown in Structural Formula (II) is a numbering system for the atoms in the core tricylic structure. - Cannabinoids also generally have a linear alkyl side chain at position C-3 of the cannabinoid core. In the cannabinoids of the present invention, the linear alkyl side chain is replaced with a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system.
- Suitable substituents for a cannabinoid include groups which do not significantly diminish the ability of a cannabinoid to activate a cannabinoid receptor. Substitutions can occur at
positions 2, 4, 6a-10a or at the three methyl groups. Substitutions at more than one position are possible. Substituents which do no significantly diminish the biological activity of cannabinoids are generally small, pharmacophoric groups. Examples include —H, —OH, —OCH3, —OCH2CH3, halogen (e.g., chloro, bromo, iodo and fluoro), —CN, azido, isocyanate, isothiocyanate, —NO2, —CH3, —C(halogen)3, —CH2O H, 13 CH2OCH3, —CH2OCH2CH3, —CH2 (halogen), —CH2CN, —CH2NO2, —CH2CH3, —CH2C(halogen)3, —CH2NH2, —CH2NHCH3 or —CH2N(CH3)2. Suitable substituents can be identified by testing modified cannabinoids in the in vitro CB1 or CB2 assays described in Example 2. Cannabinoids with other substituents can be prepared by modification of the synthetic procedures described in Example 1, e.g., by replacing alcohol (A) in the synthesis shown inFIG. 3 or by replacing the ester/ketone starting material inFIG. 4 with suitably substituted analogs. -
- Ring A has from zero to three endocyclic double bonds. Examples include wherein Ring A is completely saturated, wherein Ring A has three double bonds and wherein Ring A as one endocyclic double bond which connects carbons 9 and 10 or 9 and 11. Preferably, Ring A has one endocyclic double bond wich connects carbons 8 and 9. As used herein, a double bond between two ring atoms is an “endocyclic” double bond.
- Z is >C(CH3)2 or —C═O. Z is preferably >C(CH3)2.
- R2 is —H, —OH, —OCH3, —OCH2CH3, halogen (e.g., chloro, bromo, iodo and fluoro), —CN, —NO2, —CH3, —C(halogen)3, —CH2OH, —CH2OCH3, —CH2OCH2CH3, —CH2(halogen), —CH2CN, —CH2NO2, —CH2CH3, —CH2C(halogen)3, —CH2NH2, —CH2NHCH3 or —CH2N(CH3)2. Preferably, R2 is —CH3 or —CH2OH.
- When the tricyclic cannabinoid core is represented by Structural Formula (III), X and Y, taken together, are a C5-C7 carbocyclic ring, a substituted C5-C7 carbocyclic ring, a C5-C7 heterocyclic ring or a C5-C7 substituted heterocyclic ring.
- Carbocyclic rings are non-aromatic rings which have only carbon as the ring atoms. Preferably, carbocyclic rings include from about five to about seven ring carbons and are substituted or unsubstituted. Examples include substituted and unsubstituted cyclopentane, cyclopentene, cyclohexane, cyclohexene, cycloheptane and cycloheptene. A preferred example is a substituted cyclohexane shown below in Structural Formula (IV):
- R3 is —H or —CH3.
- R4 and R5 are independently —H, a C1-C8 straight chained alkyl group or a C1-C8 substituted straight chained alkyl group. Preferably, at least one of R4 and R5 is —H.
- Heterocyclic rings are non-aromatic rings with carbon and one or more heteroatoms such oxygen, nitrogen and/or sulfur as ring atoms. Preferably, heterocyclic rings contain from about five to about seven ring atoms and are substituted or unsubstituted. Preferred examples of heterocyclic rings are shown below in Structural Formulas (V) and (VI):
- Z′ and Z″ are independently —S—, —O—, —S(O)— or —N(R7)—. Preferably, Z′ and Z″ are each —O—0 or —S—.
- R6 is a C1 to about C12 straight chained alkyl or substituted alkyl group. Preferably, R6 is a C4 to C10 alkyl group.
- R7 is —H or —CH3.
- Other examples of hetetocyclic rings include substituted and unsubstituted 1,3-dioxane, 1,4-dioxane, 1,3-dithiane, 1,4-dithiane, diazetane, tetrahydrofuran, tetrahyrothiophene, morpholine, thiomorpholine, pyrrolidine, piperazine, piperidine and thiazolidine.
-
- R8 is —H or —CH3; and
- R9 is —H, a C1-C4 alkyl group or a C1-C4 substituted or unsubstituted alkyl group.
- A “bridged bicyclic ring” has two rings in which more than two ring atoms are shared by the two rings. Optionally, a bicyclic ring can have one or more ring heteroatoms such as oxygen, sulfur or nitrogen. A preferred bridged bicyclic ring is a substituted or unsubstituted 2.2.1 seven-membered system also referred to as a “norbornyl group”. Examples of norbornyl groups are represented by Structural Formula (VIII) and (IX);
- R10-R12 are independently —H, C1-C3 alkyl group or C1-C3 substituted alkyl group. Preferably, R10-R12 are independently —H or —CH3.
- Other examples of suitable bridged bicyclic structures include a 3.2.1 eight-membered bicyclic structure, a 3.3.1 nine-membered bicyclic structure and a 2.2.2 eight-membered structure and a 3.3.2 nine-membered structure. The structures of a 3.2.1 eight-membered bicyclic system, a 3.3.1 nine-membered bicyclic system, a 2.2.2 eight-membered. bicyclic system and a 3.3.2 nine-membered bicyclic system are provided by Structural Formulas (X)-(XIII):
In one example, the bridged bicyclic structures represented by Structural Formulas (X)-(XIII) are substituted by one or more methyl groups. - The nomenclature for bridged bicyclic and tricyclic ring systems indicates the number of ring atoms between bridgeheads. A “bridgehead” is an atom shared by both rings. For example, bicyclo 2.2.1. heptane, shown in Structural Formula (VIII), has two (C-2 and C-3), two (C-5 and C-6) and one (C-7) carbons between the bridgeheads (C-1 and C-4). The numbering scheme for the ring atoms in 2.2.1 heptane is also shown in Structural Formula (VIII).
- Bridged tricyclic ring systems comprise three rings, each of which shares two or more ring atoms with each of the other two rings. Optionally, a bridged tricyclic ring can have one or more heteroatoms such as oxygen, nitrogen or sulfur. A preferred example is a substituted or unsubstituted 1,1,1,1,1,1-tricyclic ten-membered ring system, also referred to as an “adamantyl” group. Examples of adamantyl groups are represented by Structural Formula (XIV)-(XVII):
- R13, R14, R15 and R16 are independently —H, a C1-C3 alkyl group or a C1 to C3 substituted alkyl group. Preferably, R13 is —CH3.
- X1 and X2 independently are >N— or >CH—. Preferably, X1 and X2 are >CH—.
- In another preferred embodiment, the novel cannabinoid analogs of the present invention are represented by Formula (III), modified so that the hydroxyl group attached to the phenyl ring is replaced with an —H and/or modified so that the side chain is attached to position four of the tricyclic cannabinoid core.
- Another example of suitable bridged tricyclic system is a substituted or unsubstituted 0,1,1,1,1,1-tricyclic nine-membered ring system.
- Suitable substituents for a carbocyclic ring, a heterocyclic ring, a fused bicyclic ring, a bridged bicyclic ring and a bridged tricyclic ring are generally C1-C8 alkyl groups, substituted C1-C8 alkyl groups and small, pharmacophoric groups. Examples of small, pharmacophoric groups include, but are not limited to, —H, —OH, —OCH3, —OCH2CH3, halogen (e.g., chloro, bromo, iodo and fluoro), —CN, azido, isocyanate, isothiocyanate, —NO2, —CH3, —C(halogen)3, —CH2OH, —CH2OCH3, —CH2OCH2CH3, —CH2 (halogen) , —CH2CN, —CH2NO2, —CH2CH3, —CH2C(halogen)3, —CH2NH2, —CH2NHCH3 or —CH2N(CH3)2. Alkyl groups can be straight chained or branched. Suitable substituents for an alkyl group include small, pharmacophoric groups, as described above.
- Specific examples of the compounds of the present invention are shown in
FIGS. 1 and 2 . - In the structural formulas depicted herein, the single or double bond by which a chemical group or moiety is connected to the remainder of the molecule or compound is indicated by the following symbol:
For example, the corresponding symbol in Structural Formula (VIII) indicates that the norbornyl group, which is represented in Structural Formula (I) by Y, is connected to R or X in Structural Formula (I) by a single covalent bond with between carbon three of the norbornyl group and R or X. - A “therapeutically effective amount” is the quantity of compound which results in a desired therapeutic effect in a subject, e.g., immune system-suppression, decreased nausea in patients undergoing chemotherapy, increased appetite and/or decreased pain in individuals with AIDS Wasting Syndrome or intraocular pressure in individuals with glaucoma. The specific dosage level of active ingredient will depend upon a number of factors, including, for example, biological activity of the particular preparation, age, body weight, sex and general health of the subject being treated. Typically, a “therapeutically effective amount” of the compound ranges from about 10 mg/day to about 1000 mg/day, preferably from about 50 mg/day to about 500 mg/day.
- As used herein, a “subject” refers to a human. An “animal” refers to veterinary animals, such as dogs, cats, horses, and the like, and farm animals, such as cows, pigs, guinea pigs and the like.
- The compounds of the present invention can be administered by a variety of known methods, including orally, rectally, or by parenteral routes (e.g., intramuscular, intravenous, subcutaneous, nasal or topical). The form in which the compounds are administered will be determined by the route of administration. Such forms include, but are not limited to capsular and tablet formulations (for oral and rectal administration), liquid formulations (for oral, intravenous, intramuscular or subcutaneous administration) and slow releasing microcarriers (for rectal, intramuscular or intravenous administration). The formulations can also contain a physiologically acceptable vehicle and optional adjuvants, flavorings, colorants and preservatives. Suitable physiologically acceptable vehicles may include saline, sterile water, Ringer's solution, and isotonic sodium chloride solutions.
- The compounds of the present invention can be prepared by the syntheses shown in
FIGS. 3-5 . Specific conditions for reactions shown inFIGS. 3-5 are provided in Example 1. - Also included in the present invention are physiologically acceptable salts of the novel compounds disclosed herein. Salts of compounds containing a phenolic group or other acidic functional group can be prepared by reacting with a suitable base, for example, a hydroxide base or amine base. Salts of acidic functional groups contain a countercation such as sodium, potassium, ammonium and the like. Salts of compounds containing an amine or other basic group can be obtained, for example, by reacting with a suitable organic or inorganic acid, such as hydrogen chloride, hydrogen bromide, acetic acid, perchloric acid and the like. Compounds with quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like.
- The novel compounds of the present invention have utilities other than immunomodulation. For example, the disclosed cannabinoids can be used to screen for cells which express cannabinoid receptors (CB1 or CB2). The cells are contacted with a radiolabelled cannabinoid, washed to remove unbound compound and then counted to assess retained radioactivity. Cells which retain radioactivity bind cannabinoids and are there likely to express a cannabinoid receptor. Preferably, the cannabinoid is a CB1 or CB2 selective cannabinoid and therefore identifies cells which express the CB1 or CB2 receptor, respetively.
- The disclosed cannabinoids can also be used to identify other compounds which bind to a cannabinoid receptor. For example, radiolabelled cannabinoids can be used in place of CP-55,940 in the CB1 or CB2 assay described in Example 1. Radiolabeled cannabinoids can be prepared by, for example, by reducing the ketones used in Method II of
FIG. 5 with a suitable radiolabeled reducing agent such a tritiated sodium borohydride and oxidizing back to the ketone with a suitable oxidizing agent such as pyridinium chloro chromate (PCC). Preferably, the cannabinoid is selective for the CB1 or CB2 receptor. - The invention is illustrated by the following examples which are not intended to be limiting in any way.
- Resorcinol Synthesis
- (I). Resorcinols Synthesized by Method I in
FIG. 5 - A procedure for preparing resorcinols is described in Dominiami, et al., J. Org. Chem. 42:344 (1977). The crude resorcinols obtained by this method were purified by silica gel column chromatography eluted with a 2:1 mixture of petroleum ether and acetone.
- (II). Resorcinols Synthesized by Method II
- Preparation of 5-Bromo-3,5-Dimethoxy Benzene. 100 mmol of 3,5-dimethoxyaniline were mixed with 75 ml of 48% hydrobromic acid. 150 mmol of sodium nitrite powder were added portionally over 20 minutes with rigorous stirring. The reaction was monitored by iodine-starch test paper until the paper turned blue. The resulting diazonium salt solution was added to a pre-prepared boiling solution of 50 mmol copper (I) bromide in 7 ml of 48% hydrobromic acid. The addition was complete after 20 minutes. The reaction mixture was then heated for 30 minutes with rigorous stirring. Steam distillation of the reaction mixture provided a white solid product with a yield of 40%.
- Preparation of 1′-hydroxy-1-alkyl-3,5-dimethoxybenzene. 1 mmol of 3,5-dimethoxyphenylmagnesium bromide was prepared in 8 ml of anhydrous THF according to procedures disclosed in Harvill and Herbst, J. Org. Chem., 9:21 (1944), the entire teachings of which are incorporated herein by reference. A solution of 1.1 mmol of a suitable ketone in 2 ml of anhydrous THF was added dropwise to the Grignard reagent solution. The mixture was refluxed for 2 to 3 hours and then quenched with the addition of saturated ammonium chloride solution. After work up and purification by column chromatography, product was collected in a yield of 95%.
- Preparation of 1-alkyl-3,5-dimethoxybenzene. This compound was synthesized through lithium ammonia reduction of 1′-hydroxy-1-alkyl-3,5-dimethoxybenzene by the method described in Gray et al., J. Org. Chem., Vol. 40:3151 (1975), the entire teachings of which are incorporated herein by reference.
- Preparation of 5-alkyl-resorcinol. This resorcinol was perpetrated by demethylation of 1-alkyl-3,5-dimethoxybenzene through the method described in Dominiami, et al., J. Org. Chem. 42:344 (1977), the entire teachings of which are incorporated herein by reference.
- (III) Resorcinols Synthesized by Method III in
FIG. 5 - Preparation of 1-alkyl-3,5-dimethoxybenzene. A ethereal 10 mmol of 3,5-dimethoxybenzylmagnesium bromide was prepared in the usual manner with 40 ml of anhydrous ether according to procedures disclosed in Harvill and Herbst, J. Org. Chem., 9:21 (1944). The solution of Grignard reagent was concentrated to 15 ml and transferred into an Ace pressure tube containing a 10 ml ethereal solution of 10 mmol of a suitable tertiary alkyl bromide. The mixture was sealed and heated in a 100° C. oil bath with stirring for 30 minutes, as described in Osama, et al., J. Org. Chem., 36:205 (1971), Ohno, et al., J. Org. Chem., 53:729 (1988) and Love, et al., J. Med. Chem., 16:1200 (1973), the entire teachings of which are incorporated herein by reference. The crude product was purified through column chromatoghraphy with a yield about 25%.
- Preparation of 5-alkyl-resorcinol. This resorcinol was prepared by demethylation of 1-alkyl-3,5-dimethoxybenzene by methods described in Dominiami, et al., J. Org. Chem., 42:344 (1977), the entire teachings of which are incorporated herein by reference.
- (IV). Resorcinols Synthesized by Method IV in
FIG. 5 - The procedure for the preparation of these resorcinols is the same as described in (III), except that the Grignard reagent was prepared using tetrahydrofuran.
- (V). Resorcinols Synthesized by Method V in
FIG. 5 - A mixture of 100 mmol resorcinol and 100 mmol tertiary alcohol in 200 ml of 70% methanesulfonic acid was stirred at 0° C. for 12 hours for the preparation of linear side chain resorcinols, and stirred for 3 to 4 hours at room temperature for preparation of cyclic side chain resorcinols. The reaction was quenched by addition of an excess of water. The crude product was purified by column chromatography. The column was eluted with 2:1 mixture of. petroleum ether and acetone. Yield was about 70%.
- Synthesis of Δ8-Tetrahydrocannabinol Analogs Via the Method of
Scheme 1 ofFIG. 3 . - A mixture of 1 mmol of the resorcinol, 1 mmol trans-p-mentha-2, 8-dien-1-ol and 18 mg of p-toluenesulfonic acid monohydrate in 10 ml of chloroform was stirred and heated in a 70° C. oil bath for 2 to 4 hours. Then the reaction temperature was lowered to room temperature and quenched by addition of 5 ml of saturated sodium bicarbonate solution. After separation, the aqueous layer was extracted twice with methylene chloride. The combined organic layer was washed with brine and dried over sodium sulfate. Removal of solvent by vacuum evaporation provides a yellow oil crude product. The product was purified by column chromatography. By eluting with 20:1 mixture of petroleum ether and ethyl acetate. The yield was generally about 65%. For some stereoisomers, HPLC purification was performed with a chiral column. The mobil phase was a mixture of hexane and isopropanol.
- Synthesis of 1-Deoxy-Δ8-Tetrahydrocannabinol Via the Method of
Scheme 2 inFIG. 3 - A mixture of 1 mmol of the phenol, 3 mmol trans-p-mentha-2, 8-dien-1-01 and 35 mg of p-toluenesulfonic acid monohydrate in 10 ml of chloroform was stirred and heated in a 70° C. oil bath for 4 to 8 hours. Then the reaction temperature was lowered to room temperature. The reaction was quenched by addition of 5 ml of saturated sodium bicarbonate solution. After separation, the aqueous layer was extracted twice by methylene chloride. The combined organic layer was washed by brine and dried over sodium sulfate. Removal of solvent by vacuum evaporation provided a yellow oil crude product. The product was purified by column chromatography, eluting with 20:1 mixture of petroleum ether and ethyl acetate. The yield was generally about 15% to 20%.
- Synthesis of Cannabinol and 1-Deoxy-Cannabinol Analogs Via the Method of
Scheme 3 ofFIG. 4 - The experimental procedures are as described in Love, et al., J. Med. Chem., 16:1200 (1973), Meltzer, et al., Synthsis, 1981, 985, and Gareau, et al., Bioorg. Med. Chem. Lett., 6:189 (1996), the entire teachings of which are incorporated herein by reference.
- Radioligand Binding assay
- The binding affinities of the novel compounds described in this invention for the central cannabinoid receptor was assessed using rat forebrain membranes as a source of CB1. Membranes were prepared as described by the method of Dodd et al., Brain Res. 226:107 (1981), the entire teachings of which are incorporated herein by reference. Rat whole brains minus the cerebral cortex were diced with a razor blade and homogenized in 0.32 M sucrose, pH 7.4. The resulting suspension was spun at 400×g at 4° C. The supernatant was decanted and layered over 1.2 M sucrose in TME buffer (25 mM Tris base, 5
mM MgCl 2 1 mMEDTA, pH 7.4) and spun at 109,000×g. The interface containing plasma membrane protein was collected, pooled and layered over 0.8 M sucrose in TME, pH 7.4. The pellet was carefully resuspended in TME, pH 7.4 and the total protein content was assayed by the method of Markwell et al., Anal. Biochem. 87:206 (1978), the entire teachings of which are incorporated herein by reference. Protein was aliquotted, frozen under liquid nitrogen and stored at −80° C. until use. - Approximately 30 μg of tissue was incubated in silanized 96 well microtiter plate with TME containing 0.1% essentially fatty acid free bovine serum albumin (BSA), 0.8 nM CH3]CP-55,940 and various concentrations of the test compound in a final volume of 200 μL. Assays were incubated at 30° C. for 1 hour. The samples were filtered using Packard Filtermate 196 and Whatman GF/C Filterplates and washed with wash buffer (TME) containing 0.5% BSA. Radioactivity was detected using MicroScint 20 scintillation cocktail added directly to the dried filterplates, and the filterplates were counted using a Packard Instruments Top-Count. Nonspecific binding was assessed using 100 nM CP-55,940. Data collected from three independent experiments performed with duplicate determinations were normalized between 100% and 0% specific binding for [H3]CP-55,940, determined using buffer and 100 nM CP-55,940. The normalized data was analyzed using a 4 parameter nonlinear logistic equation to yield IC50 values. Data from at least two independent experiments performed in duplicate were used to calculate IC50 values which were convered to Ki values using the assumptions of Cheng and Prusoff, Biochem. Pharmacol., 22:3099 (1973), the entire teachings of which are incorporated herein by reference.
- Mouse spleen was used a source of CB2 receptors to assess binding affinity of analogs described in this invention. The CB2 binding assay was conducted in the same manner as for CB1. Silanized centrifuge tubes were used throughout to minimize receptor loss due to adsorption.
- The Kis (nanomolar) for a number of the compounds of the present invention are shown in the Table below:
TABLE Ki in nM for the Ki in nM for the Compound CB1 Receptor CB2 Receptor AM405 19.1 AM406 14.5 AM410 25.8 22.3 AM409 75.3 AM407 9.1 AM408 18.3 AM412 182.9 85.0 AMG3 0.32 1.7 AMG9 3.6 AMG14 0.2 AM411 6.9 52.0 AM722 78.2 40.3 AM729 29.3 26.9 AM723 382.6 2845.0 AM728 30.7 32.8 AM731 60.6 6.1 AM732 20.1 2.0 - While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (26)
1. A compound represented by the following structural formula:
R—X—Y;
and physiologically acceptable salts thereof, wherein:
R is a tricyclic core of a cannabinoid or substituted cannabinoid;
X is a covalent bond, —CH2— or —CHR1—, wherein R1 is a C1 to C3 substituted or unsubstituted lower alkyl group; and
Y is a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system;
with the provisos that:
a) if the tricyclic core has an A ring with a double bond in a tricyclic core 8.9 position, a (CH3)2 group in a tricyclic core 6 position, and if X is a covalent bond in a tricyclic core 3 position, then Y cannot be:
wherein R6 is H, a C4 to about C6 alkyl group or a dialkyl group; and
b) if the tricyclic core has an A ring with three endocyclic double bonds, a ring O in a tricyclic core 5 position, a ═O group in a tricyclic core 6 position and if X is a covalent bond in a tricyclic core 3 position, then Y cannot be the following structural formulas:
where Z′ and Z″ are each independently selected from C, O, S and NH and n is an integer from 3-5; or
where Q is H, (CH2)nCH3, and n is a maximum of 7.
2. The compound of claim 1 wherein R is represented by the following structural formula:
wherein ring A has zero to three endocyclic double bonds;
Z is >C(CH3)2 or —C═O; and
R2 is —H, —OH, —OCH3, —OCH2CH3, halogen, —CN, —NO2, —CH3, —C(halogen)3, —CH2OH, —CH2OCH3, —CH2OCH2CH3, —CH2(halogen), —CH2CN, —CH2NO2, —H2CH3, —CH2C(halogan)3, —CH2NH2, —CH2NHCH3 or —CH2N(CH3)2.
4. (canceled)
6. The compound of claim 2 wherein Y is represented by a structural formula selected from:
wherein:
Z′ and Z″ are each independently selected from —S—, —O—, or —N(R7)—;
R7 is —H or —CH3;
R6 is selected from a substituted or unsubstituted C1 to about C12 straight chained alkyl group, a substituted or unsubstituted C1 to C8 branched alkyl group, —H, —OH, —OCH3, —OCH2CH3, halogen, —CN, N3, —NCO, —NCS, —NO2, —CH3, —C(halogen)3, —CH2OH, —CH2OCH3, —CH2OCH2CH3, —CH2(halogen), —CH2CN, —CH2NO2, —CH2CH3, —CH2C(halogen)3, —CH2NH2, —CH2NHCH3 or —CH2N(CH3)2.
7. (canceled)
9.-11. (canceled)
13. (canceled)
14. The compound of claim 2 wherein Y is a substituted or unsubstituted adamantyl ring system which contains zero, one or two heteroatoms.
15.-16. (canceled)
17. A method of stimulating a CB1 or CB2 receptor in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:
R—X—Y;
and physiologically acceptable salts thereof, wherein:
R is a tricyclic core of a cannabinoid or substituted cannabinoid;
X is a covalent bond, —CH2— or —CHR1—, wherein R1 is a C1 to C3 substituted or unsubstituted lower alkyl group; and
Y is a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring systems;
with the provisos that:
a) if the tricyclic core has an A ring with a double bond in a tricyclic core 8,9 position, a (CH3)2 group in a tricyclic core 6 position, and if X is a covalent bond in a tricyclic core 3 position, then Y cannot be:
wherein R6 is H, a C4 to about C6 alkyl group, and
b) if the tricyclic core has an A ring with three endocyclic double bonds, a ring O in a tricyclic core 5 position, a ═O group in a tricyclic core 6 position and if X is a covalent bond in a tricyclic core 3 position, then Y cannot be the following structural formulas:
where Z′ and Z″ are each independently selected from C, O, S and NH and n is an integer from 3-5; or
where Q is H, (CH2)nCH3, and n is a maximum of 7.
18. The method of claim 17 wherein the compound is represented by the following structural formula:
wherein ring A has zero to three endocyclic double bonds;
Z is >C(CH3)2 or —C═O; and
R2 is —H, —OH, —OCH3, —OCH2CH3, halogen, —CN, —NO2, —CH3, —C(halogen)3, —CH2OH, —CH2OCH3, —CH2OCH2CH3, —CH2(halogen), —CH2CN, —CH2NO2, —CH2CH3, —CH2NH2, —CH2NHCH3, —CH2N(CH3)2 or —CH2C(halogen)3.
20.-23. (canceled)
24. The compound of claim 1 wherein Y is a heterocyclic ring having 5 to 7 ring atoms, a substituted heterocyclic ring having 5 to 7 ring atoms, a 5 ring atom non-dithiolane heterocyclic ring, a substituted 5 ring atom non-dithiolane heterocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system.
26. The compound of claim 2 wherein Y is represented by the following structural formula:
wherein:
R13, R14, R15 and R16 are each independently selected from H, a C1 to C3 alkyl group or a C1 to C3 substituted alkyl group;
X1, X2 and X3 are each independently selected from >N—, >CH— or >S; and
Y1, Y2, Y3 and Y4 are each independently selected from >CH2, >NH or >O.
27. The compound of claim 2 wherein Y is represented by the following structural formula:
wherein:
R13, R14, R15 and R16 are each independently selected from H, a C1 to C3 alkyl group or a C1 to C3 substituted alkyl group;
X1 and X2 are each independently selected from >N— or >CH—;
X3 is >CH—; and
Y1, Y2, Y3 and Y4 are each >CH2.
28. The compound of claim 2 represented by the following structural formula:
and physiologically acceptable salts thereof, wherein:
Y is represented by a structural formula selected from:
wherein:
Z′ and Z″ are each independently selected from —S—, —O—, or —N(R7)—;
R7 is —H or —CH3; and
R6 is selected from a substituted or unsubstituted C1 to about C12 strait chained alkyl group, a substituted or unsubstituted C1 to C8 branched alkyl group, —H, —OH, —OCH3, —OCH2CH3, halogen, —CN, N3, —NCO, —NCS, —NO2, —CH3, —C(halogen)3, —CH2OH, —CH2OCH3, —CH2OCH2CH3, —CH2(halogen), —CH2CN, —CH2NO2, —CH2CH3, —CH2C(halogen)3, —CH2NH2, —CH2NHCH3 or —CH2N(CH3)2.
29. The method of claim 18 wherein Y is represented by a structural formula selected from:
wherein:
Z′ and Z″ are each independently selected from —S—, —O—, or —N(R7)—;
R7 is —H or —CH3; and
R6 is selected from a substituted or unsubstituted C1 to about C12 straight chained alkyl group, a substituted or unsubstituted C1 to C8 branched alkyl group, —H, —OH, —OCH3, —OCH2CH3, halogen, —CN, N3, —NCO, —NCS, —NO2, —CH3, —C(halogen)3, —CH2OH, —CH2OCH3, —CH2OCH2CH3, —CH2(halogen), —CH2CN, —CH2NO2, —CH2CH3, —CH2C(halogen)3, —CH2NH2, —CH2NHCH3 or —CH2N(CH3)2.
31. The method of claim 18 wherein Y is represented by a structural formula selected from:
wherein:
R13, R14, R15 and R16 are each independently selected from H, a C1 to C3 alkyl group or a C1 to C3 substituted alkyl group;
X1, X2 and X3 are each independently selected from >N—, >CH— or >S; and
Y1, Y2, Y3 and Y4 are each independently selected from >CH2, >NH or >O.
32. The method of claim 18 wherein the compound is represented by the following structural formula:
and physiologically acceptable salts thereof;
Y is represented by a structural formula selected from:
wherein:
Z′ and Z″ are each independently selected from —S—, —O—, or —N(R7)—;
R7 is —H or —CH3; and
R6 is selected from a substituted or unsubstituted C1 to about C12 strait chained alkyl group, a substituted or unsubstituted C1 to C8 branched alkyl group, —H, —OH, —OCH3, —OCH2CH3, halogen, —CN, N3, —NCO, —NCS, —NO2, —CH3, —C(halogen)3, —CH2OH, —CH2OCH3, —CH2OCH2CH3, —CH2(halogen), —CH2CN, —CH2NO2, —CH2CH3, —CH2C(halogen)3, —CH2NH2, —CH2NHCH3 or —CH2N(CH3)2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/127,455 US20050239874A1 (en) | 1998-05-04 | 2005-05-12 | Novel analgesic and immunomodulatory cannabinoids |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8400898P | 1998-05-04 | 1998-05-04 | |
US09/304,720 US20010009965A1 (en) | 1998-05-04 | 1999-05-04 | Novel analgesic and immunomodulatory cannabinoids |
US10/309,686 US6939977B2 (en) | 1998-05-04 | 2002-12-04 | Analgesic and immunomodulatory cannabinoids |
US11/127,455 US20050239874A1 (en) | 1998-05-04 | 2005-05-12 | Novel analgesic and immunomodulatory cannabinoids |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/309,686 Continuation US6939977B2 (en) | 1998-05-04 | 2002-12-04 | Analgesic and immunomodulatory cannabinoids |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050239874A1 true US20050239874A1 (en) | 2005-10-27 |
Family
ID=22182164
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/304,720 Abandoned US20010009965A1 (en) | 1998-05-04 | 1999-05-04 | Novel analgesic and immunomodulatory cannabinoids |
US10/309,686 Expired - Fee Related US6939977B2 (en) | 1998-05-04 | 2002-12-04 | Analgesic and immunomodulatory cannabinoids |
US11/127,455 Abandoned US20050239874A1 (en) | 1998-05-04 | 2005-05-12 | Novel analgesic and immunomodulatory cannabinoids |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/304,720 Abandoned US20010009965A1 (en) | 1998-05-04 | 1999-05-04 | Novel analgesic and immunomodulatory cannabinoids |
US10/309,686 Expired - Fee Related US6939977B2 (en) | 1998-05-04 | 2002-12-04 | Analgesic and immunomodulatory cannabinoids |
Country Status (6)
Country | Link |
---|---|
US (3) | US20010009965A1 (en) |
EP (1) | EP1075470B1 (en) |
AT (1) | ATE247097T1 (en) |
CA (1) | CA2340445A1 (en) |
DE (1) | DE69910373T2 (en) |
WO (1) | WO1999057106A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040087590A1 (en) * | 2002-08-23 | 2004-05-06 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
US20050119234A1 (en) * | 1999-10-18 | 2005-06-02 | University Of Connecticut | Cannabimimetic indole derivatives |
US20050137173A1 (en) * | 1999-10-18 | 2005-06-23 | Alexandros Makriyannis | Bicyclic cannabinoid agonists for the cannabinoid receptor |
US20060030563A1 (en) * | 1999-10-18 | 2006-02-09 | Alexandros Makriyannis | Novel pyrazole analogs acting on cannabinoid receptors |
US20060100208A1 (en) * | 1999-10-18 | 2006-05-11 | Alexandros Makriyannis | Pyrazole derivatives as cannabinoid receptor antagonists |
US20060199957A1 (en) * | 2001-07-13 | 2006-09-07 | Alexandros Makriyannis | Novel bicyclic and tricyclic cannabinoids |
US7741365B2 (en) | 1999-10-18 | 2010-06-22 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE277921T1 (en) * | 1998-05-04 | 2004-10-15 | Univ Connecticut | CANNABINOIDS SELECTIVELY ACTING ON THE CB2 RECEPTOR |
DE69910373T2 (en) | 1998-05-04 | 2004-04-01 | The University Of Connecticut, Farmington | ANALGETIC AND IMMUNOMODULATING CANNABINOIDS |
US7589220B2 (en) * | 1998-06-09 | 2009-09-15 | University Of Connecticut | Inhibitors of the anandamide transporter |
US7897598B2 (en) | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
US7161016B1 (en) | 1998-11-24 | 2007-01-09 | University Of Connecticut | Cannabimimetic lipid amides as useful medications |
US7276613B1 (en) | 1998-11-24 | 2007-10-02 | University Of Connecticut | Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
CA2387764A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Peripheral cannabinoid receptor (cb2) selective ligands |
US7329651B2 (en) | 2001-01-26 | 2008-02-12 | University Of Connecticut | Cannabimimetic ligands |
DE60237431D1 (en) | 2001-01-29 | 2010-10-07 | Univ Connecticut | RECEPTOR-SELECTIVE CANNABIMIMETIC AMINO ALKYLINDOLE |
CA2464333C (en) * | 2001-10-26 | 2011-07-26 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
TW200407110A (en) | 2001-11-23 | 2004-05-16 | Astrazeneca Ab | New use for the treatment of gastroesophageal reflux disease |
US7351729B2 (en) | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
CN1678303A (en) | 2002-08-23 | 2005-10-05 | 康涅狄格大学 | Keto cannabinoids with therapeutic indications |
DE602004031221D1 (en) * | 2003-05-20 | 2011-03-10 | Univ Tennessee Res Foundation | CANNABINOID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
CN100540005C (en) * | 2003-12-17 | 2009-09-16 | 欧加农股份有限公司 | Trinucleated 1-[(3-indol-3-yl as the cannabinoid CB 1 receptor agonist) carbonyl] bridged piperazine derivatives |
EP1696930B1 (en) | 2003-12-17 | 2007-04-11 | N.V. Organon | Tricyclic 1-((3-indol-3-yl)carbonyl)piperazine derivatives as cannabinoid cb1 receptor agonists |
WO2005123053A2 (en) * | 2004-06-22 | 2005-12-29 | Pharmos Limited | Use of cb2 receptors agonists for the treatment of huntington’s disease |
US20060206139A1 (en) * | 2005-01-19 | 2006-09-14 | Tekulve Kurt J | Vascular occlusion device |
TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
KR100892596B1 (en) * | 2007-02-12 | 2009-04-09 | 바이오스펙트럼 주식회사 | Biphenyl Diol Derivatives and Compositions Comprising the Same as an Active Ingredient |
KR101048594B1 (en) | 2009-05-04 | 2011-07-12 | 영남대학교 산학협력단 | Pharmaceutical composition containing cannabinoid derivatives that inhibit angiogenesis and cancer growth |
Citations (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3041343A (en) * | 1959-10-14 | 1962-06-26 | Sandoz Ltd | 4-(thienyl-2'')-and 4-(pyridyl-3'')-5-aminopyrazoles |
US3465024A (en) * | 1966-11-14 | 1969-09-02 | Allied Chem | Process for the preparation of isocyanates |
US3573327A (en) * | 1970-03-23 | 1971-03-30 | Searle & Co | 3-(lower alkoxy)-7,8,9,10-tetrahydro-6h-dibenzo-(b,d) pyran-6,9-diones and derivatives thereof |
US3577458A (en) * | 1966-11-14 | 1971-05-04 | Allied Chem | Process for the preparation of isocyanates |
US3656906A (en) * | 1970-04-13 | 1972-04-18 | Little Inc A | Method for detecting and quantitating the presence of cannabinoids and analogs thereof in biological materials and resulting products |
US3838131A (en) * | 1972-04-03 | 1974-09-24 | Pfizer | Di(dialkylamino alkoxy)phenanthridines as antiviral agents |
US3886184A (en) * | 1973-08-03 | 1975-05-27 | Lilly Co Eli | Aminodibenzo(b,d)pyrans |
US3897306A (en) * | 1973-07-06 | 1975-07-29 | Schering Ag | 7-Hydroxy-delta 8-tetrahydrocannabinols and microbiological production thereof |
US3915996A (en) * | 1972-10-16 | 1975-10-28 | Abbott Lab | Process for making benzopyrans |
US3928598A (en) * | 1973-11-05 | 1975-12-23 | Lilly Co Eli | Hexahydro-dibenzo{8 b,d{9 pyran-9-ones as an anti-anxiety drug |
US3944673A (en) * | 1973-11-05 | 1976-03-16 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as analgesic drugs |
US3946029A (en) * | 1973-02-16 | 1976-03-23 | Labaz | Indole derivatives |
US3953603A (en) * | 1973-11-05 | 1976-04-27 | Eli Lilly And Company | Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs |
US4036857A (en) * | 1976-02-02 | 1977-07-19 | Sharps Associates | Benzopyrans having an unsaturated side chain |
US4054582A (en) * | 1976-07-06 | 1977-10-18 | Eli Lilly And Company | Process for converting cis-hexahydrodibenzo[b,d]pyran-9-ones to trans-hexahydrodibenzo[b,d]-pyran-9-ones |
US4087546A (en) * | 1976-02-17 | 1978-05-02 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as antiasthmatic drugs |
US4087547A (en) * | 1976-02-17 | 1978-05-02 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones in treatment of glaucoma |
US4087545A (en) * | 1976-02-17 | 1978-05-02 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as antiemetic drugs |
US4088777A (en) * | 1976-02-17 | 1978-05-09 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as anticonvulsant drugs |
US4102902A (en) * | 1976-11-10 | 1978-07-25 | Eli Lilly And Company | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor |
US4152450A (en) * | 1978-02-17 | 1979-05-01 | Eli Lilly And Company | 9-Amino-dibenzopyrans |
US4171315A (en) * | 1978-03-31 | 1979-10-16 | Eli Lilly And Company | Preparation of cis-hexahydrodibenzopyranones |
US4176233A (en) * | 1976-11-10 | 1979-11-27 | Eli Lilly And Company | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor |
US4179517A (en) * | 1976-01-12 | 1979-12-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Novel tetrahydrocannabinol type compounds |
US4188495A (en) * | 1977-11-14 | 1980-02-12 | Pfizer Inc. | 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor |
US4208351A (en) * | 1976-11-10 | 1980-06-17 | Eli Lilly And Company | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor |
US4278603A (en) * | 1973-11-05 | 1981-07-14 | Eli Lilly And Company | Novel polymorphic crystalline form of dibenzopyranone |
US4282248A (en) * | 1978-08-02 | 1981-08-04 | Raphael Mechoulam | Pinene derivatives and pharmaceutical compositions containing the same |
US4382943A (en) * | 1980-07-04 | 1983-05-10 | Boehringer Mannheim Gmbh | Anti-allergic aryl ether derivatives |
US4395560A (en) * | 1982-05-24 | 1983-07-26 | Eli Lilly And Company | Preparation of 6a,10a-trans-hexahydrodibenzopyranones |
US4497827A (en) * | 1982-08-30 | 1985-02-05 | Syntex (U.S.A.) Inc. | Arachidonic acid analogues as anti-inflammatory and anti-allergic agents |
US4550214A (en) * | 1981-01-05 | 1985-10-29 | Polaroid Corporation | Blocked vinyl biphenyl compounds |
US4758597A (en) * | 1987-05-15 | 1988-07-19 | University Patents, Inc. | Carenadiol and derivatives |
US4812457A (en) * | 1984-11-21 | 1989-03-14 | Research Development Corporation | Prostaglandin derivatives |
US4876276A (en) * | 1986-10-24 | 1989-10-24 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | (3S-4S)-7-hydroxy-Δ6 -tetrahydrocannabinols |
US4885295A (en) * | 1984-08-06 | 1989-12-05 | Sterling Drug Inc. | Method of use of 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles |
US5053548A (en) * | 1989-02-08 | 1991-10-01 | Otsuka Pharmaceutical Company, Ltd. | Biphenyl derivative composition for nerve cell degeneration repairing or protective agent and process for preparing a phenyl derivative contained in the composition |
US5068234A (en) * | 1990-02-26 | 1991-11-26 | Sterling Drug Inc. | 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles |
US5147876A (en) * | 1988-12-29 | 1992-09-15 | Mitsui Petrochemical Industries, Ltd. | 2,6-di,2,4,6-, 2,5,6-tri and 2,4,5,6-tetra-substituted pyrimidines, their pharmaceutically acceptable salts, pharmaceutical compositions containing same and their use in the treatment of neurological diseases |
US5223510A (en) * | 1990-08-06 | 1993-06-29 | Sanofi | Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them |
US5284867A (en) * | 1989-11-07 | 1994-02-08 | Yissum Research Development Company Of The Hebrew University In Jerusalem | NMDA-blocking pharmaceutical compositions |
US5434295A (en) * | 1994-02-07 | 1995-07-18 | Yissum Research Development Company | Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds |
US5440052A (en) * | 1993-08-06 | 1995-08-08 | University Of Connecticut | Compositions useful as a cannabinoid receptor probe |
US5462960A (en) * | 1993-12-17 | 1995-10-31 | Sanofi | Pyrazole-3-carboxamide derivatives, process for their preparation and pharmaceutical compositions in which they are present |
US5489580A (en) * | 1992-11-05 | 1996-02-06 | University Of Connecticut | Phospholipid compounds and use therefor |
US5521215A (en) * | 1989-11-07 | 1996-05-28 | Ramot University Authority For Applied Research And Industrial Development Ltd. | NMDA-blocking pharmaceuticals |
US5532237A (en) * | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
US5538993A (en) * | 1991-09-12 | 1996-07-23 | Yissum Research Development Company | Certain tetrahydrocannabinol-7-oic acid derivatives |
US5576436A (en) * | 1991-08-01 | 1996-11-19 | Pharmaceutical Discovery Corporation | Fluorescent ligands |
US5605906A (en) * | 1995-03-24 | 1997-02-25 | Merck Frosst Canada, Inc. | Cannabinoid receptor agonists |
US5618955A (en) * | 1992-11-30 | 1997-04-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Fatty acid derivatives and pharmaceutical compositions containing same |
US5624941A (en) * | 1992-06-23 | 1997-04-29 | Sanofi | Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present |
US5631297A (en) * | 1994-07-11 | 1997-05-20 | Pate; David W. | Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same |
US5635530A (en) * | 1991-09-12 | 1997-06-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them |
US5688825A (en) * | 1996-05-31 | 1997-11-18 | University Of Connecticut | Anandamide amidase inhibitors as analgesic agents |
US5747524A (en) * | 1994-07-15 | 1998-05-05 | Eli Lilly And Company | Cannabinoid receptor antagonists |
US5804601A (en) * | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
US5925628A (en) * | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5925768A (en) * | 1995-12-08 | 1999-07-20 | Sanofi | 3-pyrazolecarboxamide derivatives having cannabinoid receptor affinity |
US5932610A (en) * | 1995-09-11 | 1999-08-03 | Yissum Research Development Co. Of The Hebrew University | Tumor necrosis factor α (TNF-α) inhibiting pharmaceuticals |
US5939429A (en) * | 1997-09-30 | 1999-08-17 | Virginia Commonwealth University | Cardiovascular uses of cannabinoid compounds |
US5948777A (en) * | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
US6013648A (en) * | 1995-06-21 | 2000-01-11 | Sanofi | CB2 Receptor agonist compounds |
US6028084A (en) * | 1995-11-23 | 2000-02-22 | Sanofi-Synthelabo | Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives |
US6096740A (en) * | 1990-11-06 | 2000-08-01 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions |
US6127399A (en) * | 1996-11-15 | 2000-10-03 | Neurogen Corporation | Certain pyrazole derivatives as cortiocotropin-releasing factor receptor CRF1 specific ligands |
US6166066A (en) * | 1998-05-04 | 2000-12-26 | The University Of Connecticut | Cannabinoids selective for the CB2 receptor |
US6284788B1 (en) * | 1997-02-21 | 2001-09-04 | Bayer Aktiengesellschaft | Use of known agonists of the central cannabinoid receptor CB1 |
US6610737B1 (en) * | 2000-06-22 | 2003-08-26 | Pharmos Corporation | Non-psychotropic cannabinoids |
US6653304B2 (en) * | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
US6864291B1 (en) * | 1999-10-31 | 2005-03-08 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Agonists specific for the peripheral cannabinoid receptor |
US6900236B1 (en) * | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
US20050137173A1 (en) * | 1999-10-18 | 2005-06-23 | Alexandros Makriyannis | Bicyclic cannabinoid agonists for the cannabinoid receptor |
US6969977B1 (en) * | 2004-06-10 | 2005-11-29 | National Semiconductor Corporation | Soft-start voltage regulator circuit |
US6995187B1 (en) * | 1999-10-18 | 2006-02-07 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
US20060030563A1 (en) * | 1999-10-18 | 2006-02-09 | Alexandros Makriyannis | Novel pyrazole analogs acting on cannabinoid receptors |
US20060100208A1 (en) * | 1999-10-18 | 2006-05-11 | Alexandros Makriyannis | Pyrazole derivatives as cannabinoid receptor antagonists |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US120094A (en) * | 1871-10-17 | Improvement in apparatus for compressing air | ||
US119972A (en) * | 1871-10-17 | Improvement in windmills | ||
US77851A (en) * | 1868-05-12 | Hie am tayloe | ||
US149082A (en) * | 1874-03-31 | Improvement in sack-scales | ||
US77649A (en) * | 1868-05-05 | Charles parker and edmund parker | ||
US87590A (en) * | 1869-03-09 | Improved last | ||
JPS5798228A (en) | 1980-12-10 | 1982-06-18 | Hisamitsu Pharmaceut Co Inc | Biphenyl derivative |
JPH02304080A (en) | 1989-05-17 | 1990-12-17 | Toyo Pharma- Kk | 6h-dibenzo(b,d)pyran-6-one derivative, its production and use thereof |
DE69910373T2 (en) | 1998-05-04 | 2004-04-01 | The University Of Connecticut, Farmington | ANALGETIC AND IMMUNOMODULATING CANNABINOIDS |
WO1999064389A1 (en) | 1998-06-09 | 1999-12-16 | Alexandros Makriyannis | Inhibitors of the anandamide transporter as analgesic agents |
US7897598B2 (en) | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
AU1833600A (en) | 1998-11-24 | 2000-06-19 | Andreas Goutopoulos | Cannabimimetic lipid amides as useful medications |
WO2001028557A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Cannabimimetic indole derivatives |
EP1226112A4 (en) | 1999-10-18 | 2004-10-13 | Univ Connecticut | Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
CA2388503A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
AU780572B2 (en) | 1999-10-18 | 2005-04-07 | University Of Connecticut, The | Pyrazole derivatives as cannabinoid receptor antagonists |
US7329651B2 (en) | 2001-01-26 | 2008-02-12 | University Of Connecticut | Cannabimimetic ligands |
DE60237431D1 (en) | 2001-01-29 | 2010-10-07 | Univ Connecticut | RECEPTOR-SELECTIVE CANNABIMIMETIC AMINO ALKYLINDOLE |
US7057076B2 (en) | 2001-07-13 | 2006-06-06 | University Of Connecticut | Bicyclic and tricyclic cannabinoids |
AU2002331766A1 (en) | 2001-08-31 | 2003-03-18 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
CA2464333C (en) | 2001-10-26 | 2011-07-26 | University Of Connecticut | Heteroindanes: a new class of potent cannabimimetic ligands |
EP1469842A4 (en) | 2002-01-31 | 2006-04-26 | Pharmos Corp | Bicyclic cb2 cannabinoid receptor ligands |
IL147941A0 (en) | 2002-01-31 | 2002-08-14 | Pharmos Corp | Bicyclic cb2 cannabinoid receptor ligands |
US20040087590A1 (en) | 2002-08-23 | 2004-05-06 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
CN1678303A (en) * | 2002-08-23 | 2005-10-05 | 康涅狄格大学 | Keto cannabinoids with therapeutic indications |
US7671034B2 (en) * | 2003-12-19 | 2010-03-02 | Merial Limited | Stabilized formulation of ivermectin feed premix with an extended shelf life |
-
1999
- 1999-05-04 DE DE69910373T patent/DE69910373T2/en not_active Expired - Lifetime
- 1999-05-04 EP EP99921637A patent/EP1075470B1/en not_active Expired - Lifetime
- 1999-05-04 US US09/304,720 patent/US20010009965A1/en not_active Abandoned
- 1999-05-04 CA CA002340445A patent/CA2340445A1/en not_active Abandoned
- 1999-05-04 AT AT99921637T patent/ATE247097T1/en not_active IP Right Cessation
- 1999-05-04 WO PCT/US1999/009701 patent/WO1999057106A1/en active IP Right Grant
-
2002
- 2002-12-04 US US10/309,686 patent/US6939977B2/en not_active Expired - Fee Related
-
2005
- 2005-05-12 US US11/127,455 patent/US20050239874A1/en not_active Abandoned
Patent Citations (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3041343A (en) * | 1959-10-14 | 1962-06-26 | Sandoz Ltd | 4-(thienyl-2'')-and 4-(pyridyl-3'')-5-aminopyrazoles |
US3465024A (en) * | 1966-11-14 | 1969-09-02 | Allied Chem | Process for the preparation of isocyanates |
US3577458A (en) * | 1966-11-14 | 1971-05-04 | Allied Chem | Process for the preparation of isocyanates |
US3573327A (en) * | 1970-03-23 | 1971-03-30 | Searle & Co | 3-(lower alkoxy)-7,8,9,10-tetrahydro-6h-dibenzo-(b,d) pyran-6,9-diones and derivatives thereof |
US3656906A (en) * | 1970-04-13 | 1972-04-18 | Little Inc A | Method for detecting and quantitating the presence of cannabinoids and analogs thereof in biological materials and resulting products |
US3838131A (en) * | 1972-04-03 | 1974-09-24 | Pfizer | Di(dialkylamino alkoxy)phenanthridines as antiviral agents |
US3915996A (en) * | 1972-10-16 | 1975-10-28 | Abbott Lab | Process for making benzopyrans |
US3946029A (en) * | 1973-02-16 | 1976-03-23 | Labaz | Indole derivatives |
US3897306A (en) * | 1973-07-06 | 1975-07-29 | Schering Ag | 7-Hydroxy-delta 8-tetrahydrocannabinols and microbiological production thereof |
US3886184A (en) * | 1973-08-03 | 1975-05-27 | Lilly Co Eli | Aminodibenzo(b,d)pyrans |
US3944673A (en) * | 1973-11-05 | 1976-03-16 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as analgesic drugs |
US3953603A (en) * | 1973-11-05 | 1976-04-27 | Eli Lilly And Company | Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs |
US3928598A (en) * | 1973-11-05 | 1975-12-23 | Lilly Co Eli | Hexahydro-dibenzo{8 b,d{9 pyran-9-ones as an anti-anxiety drug |
US4278603A (en) * | 1973-11-05 | 1981-07-14 | Eli Lilly And Company | Novel polymorphic crystalline form of dibenzopyranone |
US4179517A (en) * | 1976-01-12 | 1979-12-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Novel tetrahydrocannabinol type compounds |
US4036857A (en) * | 1976-02-02 | 1977-07-19 | Sharps Associates | Benzopyrans having an unsaturated side chain |
US4087546A (en) * | 1976-02-17 | 1978-05-02 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as antiasthmatic drugs |
US4087547A (en) * | 1976-02-17 | 1978-05-02 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones in treatment of glaucoma |
US4087545A (en) * | 1976-02-17 | 1978-05-02 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as antiemetic drugs |
US4088777A (en) * | 1976-02-17 | 1978-05-09 | Eli Lilly And Company | Hexahydro-dibenzo[b,d]pyran-9-ones as anticonvulsant drugs |
US4054582A (en) * | 1976-07-06 | 1977-10-18 | Eli Lilly And Company | Process for converting cis-hexahydrodibenzo[b,d]pyran-9-ones to trans-hexahydrodibenzo[b,d]-pyran-9-ones |
US4208351A (en) * | 1976-11-10 | 1980-06-17 | Eli Lilly And Company | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor |
US4102902A (en) * | 1976-11-10 | 1978-07-25 | Eli Lilly And Company | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor |
US4176233A (en) * | 1976-11-10 | 1979-11-27 | Eli Lilly And Company | Stereoselective preparation of hexahydro dibenzopyranones and intermediates therefor |
US4188495A (en) * | 1977-11-14 | 1980-02-12 | Pfizer Inc. | 1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor |
US4152450A (en) * | 1978-02-17 | 1979-05-01 | Eli Lilly And Company | 9-Amino-dibenzopyrans |
US4171315A (en) * | 1978-03-31 | 1979-10-16 | Eli Lilly And Company | Preparation of cis-hexahydrodibenzopyranones |
US4282248A (en) * | 1978-08-02 | 1981-08-04 | Raphael Mechoulam | Pinene derivatives and pharmaceutical compositions containing the same |
US4382943A (en) * | 1980-07-04 | 1983-05-10 | Boehringer Mannheim Gmbh | Anti-allergic aryl ether derivatives |
US4550214A (en) * | 1981-01-05 | 1985-10-29 | Polaroid Corporation | Blocked vinyl biphenyl compounds |
US4395560A (en) * | 1982-05-24 | 1983-07-26 | Eli Lilly And Company | Preparation of 6a,10a-trans-hexahydrodibenzopyranones |
US4497827A (en) * | 1982-08-30 | 1985-02-05 | Syntex (U.S.A.) Inc. | Arachidonic acid analogues as anti-inflammatory and anti-allergic agents |
US4885295A (en) * | 1984-08-06 | 1989-12-05 | Sterling Drug Inc. | Method of use of 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles |
US4812457A (en) * | 1984-11-21 | 1989-03-14 | Research Development Corporation | Prostaglandin derivatives |
US4876276A (en) * | 1986-10-24 | 1989-10-24 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | (3S-4S)-7-hydroxy-Δ6 -tetrahydrocannabinols |
US4758597A (en) * | 1987-05-15 | 1988-07-19 | University Patents, Inc. | Carenadiol and derivatives |
US5147876A (en) * | 1988-12-29 | 1992-09-15 | Mitsui Petrochemical Industries, Ltd. | 2,6-di,2,4,6-, 2,5,6-tri and 2,4,5,6-tetra-substituted pyrimidines, their pharmaceutically acceptable salts, pharmaceutical compositions containing same and their use in the treatment of neurological diseases |
US5053548A (en) * | 1989-02-08 | 1991-10-01 | Otsuka Pharmaceutical Company, Ltd. | Biphenyl derivative composition for nerve cell degeneration repairing or protective agent and process for preparing a phenyl derivative contained in the composition |
US5521215A (en) * | 1989-11-07 | 1996-05-28 | Ramot University Authority For Applied Research And Industrial Development Ltd. | NMDA-blocking pharmaceuticals |
US5284867A (en) * | 1989-11-07 | 1994-02-08 | Yissum Research Development Company Of The Hebrew University In Jerusalem | NMDA-blocking pharmaceutical compositions |
US5324737A (en) * | 1990-02-26 | 1994-06-28 | Sterling Winthrop Inc. | 3-arylcarbonyl-1-(C-attached-N-heteryl)-1H-indoles |
US5607933A (en) * | 1990-02-26 | 1997-03-04 | Sterling Winthrop Inc. | 3-arylcarbonyl-1(C-attached-N-heteryl)-1H-indoles |
US5817651A (en) * | 1990-02-26 | 1998-10-06 | Sanofi | 3-arylcarbonyl-1-(C-attached-N-heteryl)-1H-indoles |
US5068234A (en) * | 1990-02-26 | 1991-11-26 | Sterling Drug Inc. | 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles |
US5223510A (en) * | 1990-08-06 | 1993-06-29 | Sanofi | Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them |
US6096740A (en) * | 1990-11-06 | 2000-08-01 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions |
US5576436A (en) * | 1991-08-01 | 1996-11-19 | Pharmaceutical Discovery Corporation | Fluorescent ligands |
US5538993A (en) * | 1991-09-12 | 1996-07-23 | Yissum Research Development Company | Certain tetrahydrocannabinol-7-oic acid derivatives |
US5635530A (en) * | 1991-09-12 | 1997-06-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them |
US5624941A (en) * | 1992-06-23 | 1997-04-29 | Sanofi | Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present |
US5744459A (en) * | 1992-11-05 | 1998-04-28 | University Of Connecticut | Phospholipid compounds and use therefor |
US5489580A (en) * | 1992-11-05 | 1996-02-06 | University Of Connecticut | Phospholipid compounds and use therefor |
US5618955A (en) * | 1992-11-30 | 1997-04-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Fatty acid derivatives and pharmaceutical compositions containing same |
US5440052A (en) * | 1993-08-06 | 1995-08-08 | University Of Connecticut | Compositions useful as a cannabinoid receptor probe |
US5872148A (en) * | 1993-08-06 | 1999-02-16 | University Of Connecticut | Compositions useful as a cannabinoid receptor probe |
US5462960A (en) * | 1993-12-17 | 1995-10-31 | Sanofi | Pyrazole-3-carboxamide derivatives, process for their preparation and pharmaceutical compositions in which they are present |
US5434295A (en) * | 1994-02-07 | 1995-07-18 | Yissum Research Development Company | Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds |
US5631297A (en) * | 1994-07-11 | 1997-05-20 | Pate; David W. | Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same |
US5747524A (en) * | 1994-07-15 | 1998-05-05 | Eli Lilly And Company | Cannabinoid receptor antagonists |
US5532237A (en) * | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
US5605906A (en) * | 1995-03-24 | 1997-02-25 | Merck Frosst Canada, Inc. | Cannabinoid receptor agonists |
US5804601A (en) * | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
US6013648A (en) * | 1995-06-21 | 2000-01-11 | Sanofi | CB2 Receptor agonist compounds |
US5932610A (en) * | 1995-09-11 | 1999-08-03 | Yissum Research Development Co. Of The Hebrew University | Tumor necrosis factor α (TNF-α) inhibiting pharmaceuticals |
US6028084A (en) * | 1995-11-23 | 2000-02-22 | Sanofi-Synthelabo | Pyrazole derivatives, method for preparing same, and pharmaceutical compositions containing said derivatives |
US5925768A (en) * | 1995-12-08 | 1999-07-20 | Sanofi | 3-pyrazolecarboxamide derivatives having cannabinoid receptor affinity |
US5874459A (en) * | 1996-05-31 | 1999-02-23 | University Of Connecticut | Anandamide amidase inhibitors as analgesic agents |
US5688825A (en) * | 1996-05-31 | 1997-11-18 | University Of Connecticut | Anandamide amidase inhibitors as analgesic agents |
US6391909B1 (en) * | 1996-05-31 | 2002-05-21 | University Of Connecticut | Anandamide inhibitors as analgesic agents |
US6579900B2 (en) * | 1996-05-31 | 2003-06-17 | University Of Connecticut | Anandamide amidase inhibitors as analgesic agents |
US6127399A (en) * | 1996-11-15 | 2000-10-03 | Neurogen Corporation | Certain pyrazole derivatives as cortiocotropin-releasing factor receptor CRF1 specific ligands |
US6284788B1 (en) * | 1997-02-21 | 2001-09-04 | Bayer Aktiengesellschaft | Use of known agonists of the central cannabinoid receptor CB1 |
US5948777A (en) * | 1997-03-18 | 1999-09-07 | Smithkline Beecham Corporation | Cannabinoid receptor agonists |
US5925628A (en) * | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5939429A (en) * | 1997-09-30 | 1999-08-17 | Virginia Commonwealth University | Cardiovascular uses of cannabinoid compounds |
US6166066A (en) * | 1998-05-04 | 2000-12-26 | The University Of Connecticut | Cannabinoids selective for the CB2 receptor |
US6943266B1 (en) * | 1999-10-18 | 2005-09-13 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
US6900236B1 (en) * | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
US20050137173A1 (en) * | 1999-10-18 | 2005-06-23 | Alexandros Makriyannis | Bicyclic cannabinoid agonists for the cannabinoid receptor |
US6995187B1 (en) * | 1999-10-18 | 2006-02-07 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
US20060030563A1 (en) * | 1999-10-18 | 2006-02-09 | Alexandros Makriyannis | Novel pyrazole analogs acting on cannabinoid receptors |
US20060100208A1 (en) * | 1999-10-18 | 2006-05-11 | Alexandros Makriyannis | Pyrazole derivatives as cannabinoid receptor antagonists |
US6864291B1 (en) * | 1999-10-31 | 2005-03-08 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Agonists specific for the peripheral cannabinoid receptor |
US6903137B2 (en) * | 1999-10-31 | 2005-06-07 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Agonists specific for the peripheral cannabinoid receptor |
US6653304B2 (en) * | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
US6610737B1 (en) * | 2000-06-22 | 2003-08-26 | Pharmos Corporation | Non-psychotropic cannabinoids |
US6969977B1 (en) * | 2004-06-10 | 2005-11-29 | National Semiconductor Corporation | Soft-start voltage regulator circuit |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050119234A1 (en) * | 1999-10-18 | 2005-06-02 | University Of Connecticut | Cannabimimetic indole derivatives |
US20050137173A1 (en) * | 1999-10-18 | 2005-06-23 | Alexandros Makriyannis | Bicyclic cannabinoid agonists for the cannabinoid receptor |
US20060030563A1 (en) * | 1999-10-18 | 2006-02-09 | Alexandros Makriyannis | Novel pyrazole analogs acting on cannabinoid receptors |
US20060100208A1 (en) * | 1999-10-18 | 2006-05-11 | Alexandros Makriyannis | Pyrazole derivatives as cannabinoid receptor antagonists |
US7241799B2 (en) | 1999-10-18 | 2007-07-10 | University Of Connecticut | Cannabimimetic indole derivatives |
US7335688B2 (en) | 1999-10-18 | 2008-02-26 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
US7741365B2 (en) | 1999-10-18 | 2010-06-22 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
US7745440B2 (en) | 1999-10-18 | 2010-06-29 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
US8084467B2 (en) | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
US20060199957A1 (en) * | 2001-07-13 | 2006-09-07 | Alexandros Makriyannis | Novel bicyclic and tricyclic cannabinoids |
US7285683B2 (en) | 2001-07-13 | 2007-10-23 | University Of Connecticut | Bicyclic and tricyclic cannabinoids |
US20040087590A1 (en) * | 2002-08-23 | 2004-05-06 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
Also Published As
Publication number | Publication date |
---|---|
EP1075470B1 (en) | 2003-08-13 |
US20030120094A1 (en) | 2003-06-26 |
DE69910373T2 (en) | 2004-04-01 |
US20010009965A1 (en) | 2001-07-26 |
WO1999057106A1 (en) | 1999-11-11 |
ATE247097T1 (en) | 2003-08-15 |
EP1075470A1 (en) | 2001-02-14 |
US6939977B2 (en) | 2005-09-06 |
DE69910373D1 (en) | 2003-09-18 |
CA2340445A1 (en) | 1999-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050239874A1 (en) | Novel analgesic and immunomodulatory cannabinoids | |
US6166066A (en) | Cannabinoids selective for the CB2 receptor | |
EP1363632B1 (en) | Receptor selective cannabimimetic aminoalkylindoles | |
US7285683B2 (en) | Bicyclic and tricyclic cannabinoids | |
US20040087590A1 (en) | Novel biphenyl and biphenyl-like cannabinoids | |
RU2382040C2 (en) | Novel chroman-2-one derivatives and use thereof as monoamine neuromediator reuptake inhibitors | |
US20090069408A1 (en) | Tricyclic compounds useful in treating iron disorders | |
AU2010297263A1 (en) | Substituted N-phenyl-1-(4-pyridinyl)-1H-pyrazol-3-amines | |
WO2006090272A1 (en) | Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia | |
TW206222B (en) | ||
WO2001007427A1 (en) | Vesamicol piperazine derivatives and drugs containing the same | |
JP2022513942A (en) | Estrogen receptor antagonist | |
CN103242214A (en) | Indole derivative and preparation method thereof | |
US20070155701A1 (en) | Keto cannabinoids with therapeutic indications | |
KR102629506B1 (en) | The preparation method of Piperazine-quinoline derivative, 2-ethyl-5-(4-methyl-piperazine-1-yl)-1-(naphthalene-2-sulfonyl)-2,3-dehydro-1H-quinoline-4-on | |
JPS59205384A (en) | Hydantoin derivative | |
JP2001512491A (en) | 1- (isoquinolin-1-yl) -4- (1-phenylmethyl) piperazine; a dopamine receptor subtype-specific ligand | |
EP2487157A1 (en) | Enantioselective synthesis method of 4-aminoalcoholquinoline derivatives and the use | |
AU628400B2 (en) | Prostaglandin-derivatives having antithrombotic activity | |
US20030225154A1 (en) | Derivatives of 2-aminotetralins and pharmaceutical analogs thereof exhibiting differentail cns receptor activity and behavior | |
CN116867771A (en) | Oxadiazole substituted spiro compounds and application thereof | |
CN103275007A (en) | Pyrazole derivatives and preparation method thereof | |
WO2011073299A1 (en) | Pyridinyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators | |
CA2109420A1 (en) | Pcp receptor ligands and the use thereof | |
CN103242230A (en) | Quinolinone derivative and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF CONNECTICUT HEALTH CENTER;REEL/FRAME:027660/0807 Effective date: 20120203 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MA Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF CONNECTICUT;REEL/FRAME:039586/0230 Effective date: 20160825 |